Meetings

Explore how AI tools can revolutionize soil science, helping researchers better understand and adapt soils—and the systems they nurture—to a changing climate.

Researchers from the ECOG-ACRIN Cancer Research Group will present multiple discoveries at the American Society of Clinical Oncology Annual Meeting, including a late-breaking update from the STAMP study of pembrolizumab for Merkel cell carcinoma. Attendees can also expect primary results from studies on glioblastoma and non-small cell lung cancer, as well as exciting emerging approaches in precision oncology.

City of Hope researchers showcased new advances at ASCO 2026, highlighting progress in targeted therapies, microbiome science and blood cancers, with emerging findings in kidney, liver and prostate cancers underscoring a move toward more personalized, biology-driven treatment approaches.

Researchers from Mass General Brigham Cancer Institute will present research discoveries and outcomes from clinical trials in cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 – June 2, in Chicago 

 

ASCO brings together leading experts in clinical oncology to share the latest breakthroughs in cancer research, science and medicine. Presentations from Mass General Brigham Cancer Institute investigators include a study evaluating the outcomes of patients admitted to a dedicated oncology service within a multisite home hospital program; the results of a late-breaking plenary session on prostate cancer; efficacy and safety of a lung cancer drug; the efficacy of an app to support the psychosocial needs of patients with multiple myeloma; the creation of an electronic frailty index to inform risk ahead of CAR-T cell therapy treatments, and more.  

Below are a few highlights from this year’s presentations. All times are Central Time (CT). 

Researchers can register and submit abstracts for the first joint meeting hosted by the Endocrine Society and Keystone Symposia—an intimate meeting designed to bring together researchers to advance understanding of how hormonal signaling shapes cancer risk, progression and treatment response.

As a new research and deployment project in the EuroQCI initiative, TransEuroOGS aims to establish a network of interoperable optical ground stations for satellite-based quantum-secure communication across four EU Member States: Germany, Greece, Ireland and Luxembourg. With a budget of approximately €18 million, co-funded by the European Union and national governments, the project has now officially been kicked off with a consortium meeting in Berlin and Jena.

Doctors and researchers available for interview on breaking news and trending topics in respiratory medicine